| | |
Denominations | | US$200k/1k |
| |
CUSIP | | 302154 DL0 |
| |
ISIN | | US302154DL06 |
| |
Format | | The 2025 Notes will be registered with the U.S. Securities and Exchange Commission. |
| |
Listing | | Approval in-principle has been received from the Singapore Exchange Securities Trading Limited for the listing and quotation of the 2025 Notes. |
| |
Governing Law | | New York |
| |
Joint Bookrunners | | BNP Paribas, Citigroup Global Markets Inc., Daiwa Capital Markets Europe Limited, The Hongkong and Shanghai Banking Corporation Limited, J.P. Morgan Securities LLC, KB Securities Co., Ltd. and MUFG Securities Asia Limited |
| |
Co-manager | | KEXIM Asia Limited |
| |
Fiscal Agent | | The Bank of New York Mellon |
This Final Term Sheet should be read in conjunction with the prospectus dated July 22, 2021, as supplemented by the preliminary prospectus supplement dated January 4, 2022 (the “Preliminary Prospectus”), relating to the 2025 Notes. Capitalized terms used but not defined herein have the meanings given to them in the Preliminary Prospectus.
The Issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Issuer has filed with the Securities and Exchange Commission for more complete information about the Issuer and this offering. You may get these documents free of charge by visiting EDGAR on the website of the Securities and Exchange Commission at www.sec.gov or from J.P. Morgan Securities LLC by calling +1-212-834-4533 or HSBC Securities (USA) Inc. by calling +1-866-811-8049.
The most recent prospectus can be accessed through the following link:
https://www.sec.gov/Archives/edgar/data/0000873463/000119312522000991/d640061d424b5.htm
Notification under Section 309B(1)(c) of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”)—the Issuer has determined, and hereby notifies all relevant persons (as defined in Section 309A(1) of the SFA), that the 2025 Notes are prescribed capital markets products (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018 of Singapore) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).
ANY DISCLAIMER OR OTHER NOTICES THAT MAY APPEAR AFTER THIS MESSAGE ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER E-MAIL SYSTEM.